For research use only. Not for therapeutic Use.
CDDD11-8 (Cat No.: I040151) is a selective small-molecule inhibitor targeting CD11, a subunit of integrin receptors involved in immune cell adhesion and migration. By modulating CD11 function, CDDD11-8 interferes with leukocyte trafficking, making it a potential therapeutic for inflammatory and autoimmune diseases. Its inhibition of immune cell activation and migration could also be beneficial in cancer immunotherapy by modulating the tumor microenvironment. Preclinical studies suggest CDDD11-8’s promise in reducing inflammation and improving immune system regulation in various disease models.
| CAS Number | 2241659-94-7 |
| Synonyms | 4-N-[5-methyl-4-(6-phenylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]cyclohexane-1,4-diamine |
| Molecular Formula | C24H26N6 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H26N6/c1-16-13-27-24(28-20-10-8-19(25)9-11-20)29-23(16)21-14-26-22-12-7-18(15-30(21)22)17-5-3-2-4-6-17/h2-7,12-15,19-20H,8-11,25H2,1H3,(H,27,28,29) |
| InChIKey | OVOYRPVIZNJKHS-UHFFFAOYSA-N |
| SMILES | CC1=CN=C(N=C1C2=CN=C3N2C=C(C=C3)C4=CC=CC=C4)NC5CCC(CC5)N |
| Reference | [1]. Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel). 2022 Feb 22;14(5):1113. [2]. Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24. |
